HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Ritter, D. Articles by Virgo, K. S. Search for Related Content PubMed PubMed Citation Articles by Ritter, D. Articles by Virgo, K. S. Related Collections Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers

Troponin I in Patients without Chest Pain

Departments of¹ Pathology, ² Surgery, and ³ Cardiology, Saint Louis University School of Medicine, St. Louis, MO 63104.
⁴ John Cochran Veterans Affairs Medical Center, St. Louis, MO 63106.

^aAddress correspondence to this author at: Pathology, Saint Louis University Hospital, 3635 Vista Ave., St. Louis, MO 63110. Fax 314-268-5104; e-mail ritterdg{at}slu.edu.

Background: Testing for troponin has important clinical value for patients who present with typical symptoms of acute coronary syndromes (ACS) such as chest pain (CP). Much less is known about the value of troponin testing for patients who present with other symptoms of ACS (anginal equivalent symptoms).

Methods: The utilization and prognostic value of cardiac troponin I (cTnI) were evaluated at a Veterans Affairs Acute Care Facility. Clinical charts of 1184 predominantly male patients, who submitted specimens for initial cTnI testing by AxSYM, were evaluated for demographic data, cardiovascular risk factors, major diseases, and complaints at the time of testing. The endpoint was defined as all-cause death during a 200-day period after initial testing.

Results: Sixty-one percent of cTnI tests were ordered for patients who did not present with CP. Patients presenting with symptoms other than CP did not have significantly lower plasma cTnI than patients with CP. However, patients with symptoms other than CP were rarely diagnosed with ACS unless cTnI was 2 µg/L. The mortality during the follow-up period was severalfold higher among patients presenting with symptoms other than CP (CP, 6%; without CP, 22%; P <0.0001, ² test). cTnI 0.2 µg/L provided significant additional predictive information for patients who presented with anginal equivalent symptoms such as shortness of breath or general weakness.

Conclusion: Patients with anginal equivalent symptoms of ACS and low-positive cTnI are less often diagnosed with ACS and have a higher mortality than patients with CP.

The following articles in journals at HighWire Press have cited this article:

				D. v. d. Kerkhof, B. Peters, and V. Scharnhorst Performance of the Advia Centaur second-generation troponin assay TnI-Ultra compared with the first-generation cTnI assay Ann Clin Biochem, May 1, 2008; 45(3): 316 - 317. [Abstract] [Full Text] [PDF]